Cablivi Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high mortality of untreated attp, limitations of plasma exchange alone, approval of targeted vwf inhibitors, improved disease awareness, specialist hematology adoption.

The growth in the forecast period can be attributed to earlier diagnosis of attp, expansion of specialty hematology centers, increased access to targeted biologics, supportive reimbursement frameworks, continued innovation in rare blood disorders. Major trends in the forecast period include growing use of targeted therapies in attp, increased adoption of nanobody based drugs, focus on rapid disease control, expansion of rare hematologic treatments, improved acute care management.

Increasing clinical trials is expected to propel the growth of the cablivi market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety, efficacy, and effectiveness of medical treatments, interventions, drugs, or devices. Clinical trials are increasing due to advancements in medical research and technology, the rising incidence of chronic and complex diseases, and an aging global population that demands new treatments. Cablivi benefits from clinical trials by providing robust evidence of its efficacy and safety in treating Thrombotic Thrombocytopenic Purpura (TTP), which has led to its regulatory approval and widespread use in clinical practice. For instance, in February 2024, according to ClinicalTrials.gov, a US-based government web resource, in 2022, 4,024 clinical trials published findings, which rose to 5,063 in 2023. Therefore, increasing clinical trials is driving the growth of the cablivi market.

The rising personalized medicine is expected to propel the growth of the cablivi market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rising personalized medicine is due to advancements in genomic technologies, increased understanding of molecular biology, growing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Cablivi is beneficial through personalized medicine as it offers targeted treatment for patients with acquired thrombotic thrombocytopenic purpura (aTTP), optimizing efficacy and minimizing side effects based on individual patient characteristics and disease profiles. For instance, in February 2024, according to the Personalised Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, rising personalized medicine drives the growth of cablivi market.

Major companies operating in the cablivi market are focusing on developing advanced solutions such as warranty programs to enhance patient access and reduce financial risk. Warranty programs are structured initiatives that refund the cost of treatment for patients who do not achieve initial clinical response or who experience disease exacerbation. For instance, in January 2023, Sanofi SA, a France-based pharmaceutical and healthcare company, launched a warranty program for Cablivi, its treatment for acquired thrombotic thrombocytopenic purpura in adults. The program covers up to six inpatient doses if patients fail to reach initial clinical response and up to 12 doses for those who exacerbate during treatment. Cablivi is used alongside plasma exchange and immunosuppressive therapy to prevent dangerous blood clots. It is Sanofi’s first nanobody-based medicine and targets von Willebrand factor to inhibit its interaction with platelets. The launch reflects key features including clinical response-based reimbursement, inpatient dose coverage, support for hospital-administered therapy, and risk mitigation for high-cost treatment.

Major companies operating in the cablivi market are Sanofi S.A.

North America was the largest region in the cablivi market in 2025. The regions covered in the cablivi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cablivi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the cablivi market by increasing costs related to biologic manufacturing inputs, specialized delivery systems, and international distribution logistics. These impacts are more pronounced in regions reliant on imported biologics such as asia pacific. Treatment costs in hospital settings have experienced upward pressure. However, tariffs have encouraged regional manufacturing partnerships. This enhances long term access to life saving attp therapies.

The cablivi market research report is one of a series of new reports that provides cablivi market statistics, including cablivi industry global market size, regional shares, competitors with a cablivi market share, detailed cablivi market segments, market trends and opportunities, and any further data you may need to thrive in the cablivi industry. This cablivi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cablivi, known as caplacizumab-yhdp, is a recombinant humanized nanobody designed to inhibit the von Willebrand factor (vWF). It is used to treat acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood disorder marked by excessive clot formation in small blood vessels.

The primary clinical indications for cablivi are acquired thrombotic thrombocytopenic purpura (aTTP) and congenital thrombotic thrombocytopenic purpura (cTTP). Acquired TTP is a rare and serious condition in which blood clots form in small vessels, leading to a reduced platelet count. Cablivi is distributed through direct sales, pharmaceutical wholesalers, online pharmacies, and retail pharmacies, and is used by hospitals, clinics, ambulatory care centers, and home care providers.

The cablivi market consists of sales of cablivi injection, and cablivi treatment kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.